What Is the Recommended Dosage of 17a-Hydroxyprogesterone Acetate for Preterm Labor
2026-06-08
Preterm labor remains a leading cause of neonatal complications worldwide. For at-risk pregnant women, 17a-Hydroxyprogesterone Acetate has been a standard preventive therapy. Humanwell, a trusted pharmaceutical manufacturer, provides high-quality 17a-Hydroxyprogesterone Acetate formulations aligned with clinical guidelines.
Recommended Dosage Protocol
The standard dosage is based on major clinical trials and ACOG (American College of Obstetricians and Gynecologists) recommendations:
-
Dose: 250 mg (1 mL of 250 mg/mL suspension)
-
Route: Intramuscular (IM) injection, typically in the gluteal muscle
-
Frequency: Once weekly
-
Initiation: Between 16 and 20 weeks of gestation
-
Continuation: Until 36 weeks and 6 days of gestation or delivery, whichever occurs first
Key Clinical Data Comparison
| Parameter | Recommendation |
|---|---|
| Dosage strength | 250 mg per injection |
| Injection site | Upper outer quadrant of gluteus maximus |
| Preparation | Shake vial vigorously before use |
| Missed dose | Administer as soon as remembered; adjust schedule but never double dose |
17a-Hydroxyprogesterone Acetate FAQ
Q1: What happens if a patient misses a weekly dose of 17a-Hydroxyprogesterone Acetate?
A: If less than 7 days have passed since the missed dose, administer immediately and resume the original weekly schedule. If more than 7 days have passed, skip the missed dose entirely and give the next injection on the regular day. Do not double the dose. Humanwell advises consulting a healthcare provider to reassess therapy after any missed dose beyond 14 days.
Q2: Can 17a-Hydroxyprogesterone Acetate be used in twin pregnancies for preterm labor prevention?
A: No, current evidence does not support routine use in twin or multiple gestations. Large randomized trials showed no significant reduction in preterm birth rates for women carrying twins. Humanwell recommends using 17a-Hydroxyprogesterone Acetate only for singleton pregnancies with a prior spontaneous preterm birth history, as per FDA-approved labeling.
Q3: Are there any specific storage requirements for 17a-Hydroxyprogesterone Acetate injections from Humanwell?
A: Yes. Store vials at controlled room temperature (20°C–25°C / 68°F–77°F). Protect from light and do not freeze. If the solution appears discolored or contains visible particulates, do not inject. Humanwell ensures each vial includes a desiccant canister; keep the vial in its original carton until use.
Final Medical Guidance
Adherence to the 250 mg weekly IM protocol is critical for efficacy. All treatment decisions must involve a qualified obstetric provider. For further clinical data, safety information, or product inquiries regarding 17a-Hydroxyprogesterone Acetate, contact us at Humanwell to speak with a medical information specialist.